• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    The present invention provides a method for treating a hepatitis C virus (HCV) infected individual who has failed to respond to treatment with IFN-α but not conservative interferon-α (CIFN) or after treatment with IFN-α but not CIFN. To provide. The method generally involves administering a first dosing regimen of CIFN followed by a second dosing regimen of CIFN. Ribavirin is administered by at least a second dosing regimen.
    公开号:KR20040045022A
    申请号:KR10-2004-7004602
    申请日:2002-09-24
    公开日:2004-05-31
    发明作者:슈헨리에이치
    申请人:인터뮨, 인크.；
    IPC主号:
    专利说明:

    METHODS FOR TREATING HEPATITIS C VIRUS INFECTION IN TREATMENT FAILURE PATIENTS}
    [2] Hepatitis C virus (HCV) is the most common blood infection in the United States. Although the number of new infections has decreased, the burden of chronic infection is significant, as Centers for Disease Control predicts 3.9 million (1.8%) infected people in the United States. Chronic liver disease is one-tenth of the leading causes of death in American adults, or about 25,000 deaths or about 1% of all deaths per year. Studies show that 40% of chronic liver disease is associated with HCV, with an estimated 8,000-10,000 deaths annually. HCV-associated terminal liver disease is the most frequent indication of liver transplantation among adults.
    [3] The high incidence of chronic HCV hepatitis has important public health implications for problems addressed in the future of chronic liver disease in the United States. Data derived from the National Health and Nutrition Examination Survey (NHANES III) indicate a significant increase in the rate of new HCV infection among people between the ages of 20 and 40, particularly in the late 1960s and early 1980s. It is predicted that the number of people with HCV infection lasting 20 years or longer can quadruple from 1990 to 2015, from 750,000 to over 3 million. In people who have been infected for 30 or 40 years, the proportional increase may be greater. Since the risk of HCV-related chronic liver disease is related to the continuation of the infection, there is a constant risk of increased sclerosis in patients infected for more than 20 years, which is related to sclerosis-related morbidity and mortality among infected patients between 1965-1985. Resulting in a substantial increase.
    [4] Antiviral treatment of chronic hepatitis C has evolved rapidly in the last decade, with significant improvements in treatment efficiency. Nevertheless, 40% to 50% of patients failed treatment even with combination therapy with PEGylated IFN-α and ribavirin. Such patients are commonly referred to as "treatment failure" patients and non-responders (patients with high viral titers remaining during treatment) and relapsers (viral titers initially decrease during treatment but subsequently increase during or after treatment). Patient). Such patients currently do not have effective treatment alternatives. In particular, patients with advanced fibrosis or sclerosis on liver biopsies have a significantly increased risk of hepatocellular carcinoma as well as the risk of causing complications of advanced liver disease, including ascites, jaundice, varicella bleeding, brain disease, and advanced liver disease. Is in
    [5] Type I interferon is a cytokine with both antiviral and antiproliferative activity. Type I interferons include interferon-α (IFN-α) and interferon-β. IFN-α includes naturally occurring IFN-α, derivatives of naturally occurring IFN-α, and conservative IFN-α. Naturally occurring IFN-α used in antiviral therapies include IFN-α2a, IFN-α2b. Naturally occurring derivatives of IFN-α, ie PEGylated IFN-α's, are also used in antiviral therapy.
    [6] Conservative IFN-α's (IFN-con; IFN alfacon; CIFN) are synthetic, non-naturally occurring type IIFN-α. Conservative interferon alpha includes IFN-con 1 , IFN-con 2 , IFNcon 3 . Relative antiviral, antiproliferative and natural killer cell activity of recombinant CIFNs compared to leukocytes or other recombinant type 1 interferons and my studies show that CIFNs show significantly higher activity when compared in large quantities. Others have reported that CIFN does not cause the same side effects in patients as alpha interferon when used in the treatment of diseases susceptible to treatment with alpha interferon. The use of high doses 3 to 5 times higher than CIFN enhances the therapeutic effect and may result in substantially no corresponding increase in the frequency or intensity of undesirable side effects.
    [7] There is also a need for improved treatment for patients who have failed treatment in view of the currently available therapeutic agents. The present invention addresses this need.
    [8] Litterature
    [9] U. S. Patent No. 5,980, 884. Aliaga, S. et al., Fannacia Clinica (Spain) 14 (5): 324-331 (Jun. 1997) in Spanish with English Abstract; Bailly, F. et al., Nep Arol. Dial. Transplant. 11 (Suppl. 4): 56-57 (1996); Bizollon, T. et al., Hepatol. 26: 500-504 (1997); Brill, S. et al. , J. Hepatol. 23 (Suppl. 2): 13-16 (1995); Camps, J. et al., J. Hepatol. 19: 408-412 (1993); Davids, G. L. and Lau, J., Hepatol. 26 (Suppl. 1): 122S-127S (Sep. 1997); Davis, G. L., Gastroefaterol. Clin. N. Amer. 23 (3): 603-613 (1994); Dusheiko, G. M. et al., Br. Med. J. 312: 357-364 (1996); Fried, M. W., Med. Clin. N. Amer. 80 (5): 957-972 (1996); Lindsay, K., Hepatol. 26 (Suppl. 1): 71S-77S (Sep. 1997); Mazzaferro, V. et al., Transplant. Proc. 29: 519521 (1997); McHutchison, J., Hepatol. 26 (2): 505-506 (August 1997); Merican, M. I., Med. J. Malaysia 47 (3): 158-169 (1992); Poupon, R. Serfaty, L., Bull. Acad. Natle. Med. 180 (6): 1279-1289 (1996) in French w / English Abstract; Reichard, O., Scant. J. Infect. Dis. (Suppl. 95): 1-56 (1994); Saracco, G. and Rizzetto, M., Drugs 53 (1): 74-85 (1997); Schalm, S. W. and Brouwer, J. T., Sc and. J. Gastroenterol. 223: 46-49 (1997); Schalm, S. W. et al., Dig. Dis. Sci. 41 (12): 131S-134S (Dec. 1996); Scotto, G. et al., Ital. J. Gastroenterol. 28: 505-511 (1996); Scotto, G. et al., J. Cliemother. 7 (1): 58-61 (1995); Theod or, E. and Regev, A., Harefuah 132 (6): 402-403,447 (1997) in Hebrew with English Abstract; Thomas, H. C. et al., Drugs 52 (Suppl. 2): 1-8 (1996); Tillmann, H. and Manns, M., Kidney Blood Press. Res. 19 (3-4): 215-219 (1996); Tong, M. et al., J. Gastroenterol. Hepatol. 9: 587-591 (1994); Trepo, C. et al., Nephrol. Dial. Transplant. 11 (Suppl. 4): 62-64 (1996); Weiss, R. and Oostrom-Ram, T., Vet. Microbiol. 20: 255-265 (1989); Chemello, L. et al., J. Hepatol. 23 (Suppl. 2): 8-12 (1995); Main, J., J. Hepatol. 23 (Suppl. 2): 32-36 (1995); Schalm, S. W. et al. , J. Hepatol. 26: 961-966 (May 1997); Sherlock, S., J. Hepatol. 23 (Suppl. 2): 3-7 (1995); Braconier, J. et al., Sc and. J. Infect. Dis. 27: 325-329 (1995); Brillanti, S. et al., Gastroenterol. 107: 812-817 (1994); Chemello, L. et al. , J. Hepatol. 21 (Suppl. 1): s12 Abstract No. GS 5/29 (1994); Cohen, J., Science 285: 26-30 (2 July 1999); Lai, M-Y. et al., Gastroenterol. 111: 1307-1312 (1996); McHutchison, J. G. et al., N. Eng. J. Med. 339 (21): 1485-1491 (1998); Poynard, T. et al., The Lancet 352 (9138): 1426-1432 (1998; Schvarcz, R. et al., J. Hepatol. 23 (Suppl. 2): 17-21 (1995); and Schvarcz, R. et al., J. Med. Virol. 46 (1): 43-47 (1995)
    [10] Melian and Plosker (2001) Drugs 61: 1-31; Heathcote et al. (1998) Hepatol. 27: 11361143; Heathcote et al. (1999) Hepatol. 30: 562-566; Sjogren et al. (Apr. 30,2000) 35th Annual Meteting of the European Association for the Study of the liver Rotterdam; Chow et al. (1998) Hepatol. 27: 1144-1148; Chemello et al. (1997) C. Gastroenterol. 113: 1654-1659; Davis et al. (1998) N. Engl. J. Med. 339: 1493-1499; Kaiser et al. (April 20,2001) 36th Annual Meeting of the European Association for the Study of the Liver, Prague; Sjogren (April 20,2001) 36 th Annual Meeting of the European Association for the Study of the Liver, Prague.
    [11] Summary of the Invention
    [12] The present invention provides a method for treating an individual who does not respond to treatment with IFN-α other than HCV-infected individual interferon (CIFN) or a relapsed individual after treatment with IFN-α in addition to CIFN. Methods generally relate to administering a dose of CIFN and a dose of CIFN over a period of time, and dosing regimen relates to dosing regimens effective to achieve sustained viral responses in an individual.
    [13] Justice
    [14] As used herein, the term “treatment failure patient” (or “treatment failure”) initially responded to HCV-infected patients (referred to as “non-responders”) or previous therapy that did not respond to previous therapy for HCV. Refers to an HCV-infected patient whose therapeutic response has not been maintained. Previous treatments may generally include IFN-α monotherapy or IFN-α combination treatment, which includes the release of antiviral agents such as IFN-α and ribavirin.
    [15] The terms "non-CIFN IFN-α treatment," and "IFN-α treatment other than CIFN," as used herein interchangeably as seen in previous IFN-α treatment, refer to IFN-α monotherapy or IFN-α combination treatment ( That is, it refers to a treatment based on IFN-α treatment other than the treatment including administration of CIFN including IFN-α and antiviral agents such as ribavirin).
    [16] As used interchangeably herein, the terms “non-CIFN IFN-α” and “IFN-α that are not CIFN” refer to IFN-α that does not match CIFN and do not limit IFN-α2a; IFN-α2b; IFN-α2C; naturally occurring IFN-α, i.e., a mixture of IFN-αnl and IFN-αn3; And derivatives, i.e., pegylated derivatives of the foregoing. This term specifically excludes "conservative IFN-α" as described below.
    [17] As used herein, the term "conservative IFN-α" (used interchangeably with "CIFN" and "IFNalpha con") includes IFN-con 1 , IFN-con 2 , IFN-con 3 , and derivatives. Synthetic interferon, ie, PEGylated derivatives. PEGylated derivatives of CIFN can be produced according to methods in the art (see US Pat. Nos. 5,985, 265; 5,382, 657; 5,559, 213; and 6,177, 074).
    [18] The term “initial viral response” used interchangeably with “initial viral response” refers to a decrease in viral titer within about 24 hours, about 48 hours, about 2 days or about 1 week after starting treatment for HCV hepatitis.
    [19] As used herein, the term “sustained viral response” (SVR; referred to as “sustained response” or “persistent response”) refers to an individual's response to treatment regimens for HCV hepatitis in terms of serum HCV titers. In general, a “sustained viral response” is found in the patient's serum for at least one month, at least two months, at least three months, at least four months, at least five months, or at least six months after the end of treatment (ie, 500 or less). , Up to 200, or up to about 100 genome copies per ml serum).
    [20] As used herein, the terms “therapeutic agent”, “treatment” and the like refer to obtaining the desired pharmaceutical and / or physiological effect. The effect is therapeutic in terms of prophylactic and / or partial or complete treatment for the disease and / or side effects resulting from the disease in terms of completely or partially preventing the disease or condition. As used herein, “therapeutic agent” includes the treatment of a disease in a mammal, particularly a human, and (a) prevents a disease occurring in a subject that is susceptible to disease but has not yet been diagnosed; (b) prevent disease, i.e. prevent progress; (c) includes alleviating the disease, such as causing relief of the disease.
    [21] The terms “individual”, “host”, “test subject”, “patient” are used interchangeably herein and refer to mammals including primates of particular interest to humans, including monkeys and humans.
    [22] Before the present invention is further described, it is to be understood that the present invention is not limited to the specific embodiments described. It is to be understood that the terminology used herein is for the purpose of describing particular embodiments only, and is not intended to be limiting, since the scope of the present invention is not limited by the appended claims.
    [23] When a set of values is provided, each intervening value between the high and low limits of the value quoted or intervened differently from that range, up to tenths of the unit of the lower limit, unless the context clearly dictates otherwise. Should be understood to be included within the invention. Such small ranges of high and low limits fall within the limits independently included in the smaller ranges, also included in the present invention, and specifically excluded from the stated ranges. Where the stated range includes one or both of the limits, the range excluding one or both of the included limits is also included in the invention.
    [24] Unless defined otherwise, all technical and scientific terms described herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Although methods and materials similar or equivalent to those described herein can be used when carrying out or testing the present invention, preferred methods and materials are now described. All publications mentioned herein are incorporated into the disclosed references and describe methods and / or materials in connection with which the publication is cited.
    [25] Unless the context clearly indicates otherwise, as used herein, the simple forms “a”, “and”, and “the” include plural forms. Thus, for example, reference to “dose” includes plural forms of dosage and reference to “method” includes reference to one or more methods and equivalents known to those skilled in the art.
    [26] Publications discussed herein are provided for disclosure prior to the filing date of the present application. Nothing herein is to be construed as a license since the preceding invention could not precede publication. In addition, the date of the publication provided is different from the date of the actual publication which needs to be independently verified.
    [1] The present invention is in the field of treating viral infections, particularly hepatitis C virus infections.
    [27] The present invention treats hepatitis C virus in an individual who has HCV infection and fails to treat, i.e., an individual who fails to respond to IFN-α treatment other than conservative interferon (CIFN) treatment or who relapses during or after discontinuing IFN-α treatment other than CIFN treatment. It provides a method for doing so. The method generally involves administering a dose of CIFN and a dose of ribavirin over a period of time. Administration of CIFN and ribavirin for a period of time is referred to herein as "dose regimen" or "therapeutic regimen". Dosage regimens of the present invention are effective in achieving sustained viral responses in treated individuals.
    [28] Administration of CIFN is approximately 3 μg to approximately 15 μg or approximately 9 μg to approximately 15 μg.
    [29] Administration of CIFN is generally administered daily, every other day, three times a week or substantially continuously.
    [30] Administration of CIFN is administered for a period of time, for example, from at least 24 weeks to at least about 48 weeks or more.
    [31] The combination of the dose of CIFN and the dose of ribavirin is, for example, at least about 0.5 log, at least about 1.0 log, at least about 1.5 log, at least about 2.0 log, at least about 2.5 log, at least compared to the pretreated virus titer. Sufficient to reduce to low viral titers such as approximately 3.0 log, at least approximately 3.5 log, at least approximately 4.0 log, at least approximately 4.5 log, or at least approximately 5 log and administration of CIFN is achieved by the end of the treatment period (in combination with ribavirin ).
    [32] When administered during the treatment periods mentioned above, the amount of CIFN administered (in combination with ribavirin) may result in undetectable levels of viral titer, from approximately 500 genome copies per ml of serum to approximately 200 genome copies per ml of serum, Or less or approximately 100 genomic copies per ml of serum.
    [33] The combination of CIFN and ribavirin affects a sustainable response (referred to as "sustained response"). Also indicates a robust response, e.g., detectable HCV RNA is at least about 1 month, at least about 2 months, at least about 3 months, at least about 4 months, at least about 5 months, or CIFN as described herein. Hyperlipavir treatment is not found in patient serum for at least about 6 months.
    [34] CIFN is administered in combination with additional antiviral agents. Additional antiviral agents are typically administered over the entire time period during which CIFN is administered. The antiviral agent is in the same formulation as the isolated formulation, simultaneously within about 48 hours, within about 36 hours, within about 24 hours, within about 16 hours, within about 12 hours, within about 8 hours, within about 4 hours, within about 2 hours , Within about 1 hour, about 30 minutes, or within about 15 minutes or less. When CIFNs and antivirals are delivered to separate formulations, CIFNs and antivirals are delivered in the same or different routes. Antiviral agents are delivered in the same or different dosage regimens, such as CIFN.
    [35] In one embodiment, the patient is treated with a combination of CIFN and ribavirin. Ribavirin, l-P-D-ribofuranosyl-lH-l, 2,4-triazole-3-carboxamide, available from ICN Pharmaceuticals, Inc., Costa Mesa, Calif. 8199, Eleventh Edition. Its preparations and formulations are described in U. S. Pat. No. 4,211, 771. The present invention also contemplates the use of derivatives of ribavirin (ie, see U. S. Pat. No. 6,277, 830). Ribavirin is administered orally in capsule or pill form, or by the same or different route as the CIFN or other dosage form. Of course, other dosage forms of both medicaments are intended, such as, as useful, nasal sprays, transdermal suppositories, sustained release dosage forms. Other forms of administration work as long as appropriate dosages are delivered without destroying the active ingredient.
    [36] Ribavirin is generally administered in an amount ranging from about 400 mg to about 1200 mg, about 600 mg to about 1000 mg, or about 700 to about 900 mg per day. In some embodiments, ribavirin is administered during the entire route of CIFN treatment. In another embodiment, ribavirin is administered only during the first period. In another embodiment, ribavirin is administered only during the second period of time.
    [37] Representative non-limiting treatment regimens include the following.
    [38] Treatment regimen 1 : 3 μg CIFN three times a week for 24 weeks. Ribavirin is administered at about 1000-1200 mg per day during the treatment regimen.
    [39] Treatment regimen 2 : 9 μg CIFN three times a week for 24 weeks. Ribavirin is administered at about 1000-1200 mg per day during the treatment regimen.
    [40] Treatment regimen 3 : 15 μg CIFN three times a week for 24 weeks. Ribavirin is administered at about 1000-1200 mg per day during the treatment regimen.
    [41] Treatment Cure 4 : 9 μg CIFN / day for 24 weeks. Ribavirin is administered at about 1000-1200 mg per day during the treatment regimen.
    [42] Treatment regimen 5 : 9 μg CIFN / day for 48 weeks. Ribavirin is administered at about 1000-1200 mg per day during the treatment regimen.
    [43] Treatment regimen 6 : 15 μg CIFN / day for 24 weeks. Ribavirin is administered at about 1000-1200 mg per day during the treatment regimen.
    [44] Treatment regimen 7 : 15 μg CIFN / day for 48 weeks. Ribavirin is administered at about 1000-1200 mg per day during the treatment regimen.
    [45] Treatment regimen 8 : 9 μg CIFN three times a week for 48 weeks. Ribavirin is administered at about 1000-1200 mg per day during the treatment regimen.
    [46] Treatment regimen 9 : 15 ug CIFN TIW for 3 weeks (3 times a week).
    [47] Ribavirin is administered at about 1000-1200 mg per day during the treatment regimen.
    [48] Treatment Cure 10 : 18 ug CIFN TIW (3 times a week) for 48 weeks.
    [49] Ribavirin is administered at about 1000-1200 mg per day during the treatment regimen. Instructions for the administration regimen for CIFN are described in Balmori Melian and Plosker (2001) Drugs 61: 1-31; US Patent No. 5,980, 884; Kaiser et al. (April 20,2001) 36 Annual Meeting of the European Association for the Study of the Liver, Prague; Bellobuono et al. (April 20,2001) 36 th Annual Meeting of the European Association for the Study of the Liver, Prague; European Agency for the Evaluation of Medicinal Products (EMEA) Guidelines; Found in US Food and Drug Administration Guidelines.
    [50] IFN-alpha
    [51] The method involves administering to a "treatment-failure" patient an amount of CIFN and ribavirin that is effective to reduce viral titer and affect a sustained viral response. Treatment failure patients include non-responders and relapsers previously treated with non-CIFN IFN-α. Such previous treatments include non-CIFN IFN-α monotherapy, non-CIFNIFN-α combination treatment (ie, non-CIFN IFN-α and ribavirin).
    [52] As used herein, the term “non-CIFN interferon-alpha” refers to an IFN-α protein that inhibits viral proliferation, cell proliferation, and an intermediate immune response other than CIFN. The term “non-CIFN interferon-alpha” includes: (1) naturally occurring IFN-a; (2) recombinant interferon alpha-2b such as Intron-A interferon available from Schering Corporation, Kenilworth, N. J .; (3) recombinant interferon alpha-2a such as roferon interferon available from Hoffmann-La Roche, Nutley, N. J .; (4) Boehringer Ingelheim Pharmaceutical, Inc. Recombinant interferon alpha-2C such as Berofor alpha 2 interferon available from Ridgefield, Conn .; (5) Interferon alpha-nl, purified mixture of natural alpha interferon such as Sumiferon available from Sumitomo, Japan or Glaxo-Wellcome Ltd. Wellferon interferon alpha-nl (INS) available from London, Great Britain; (6) Interferon alpha-n3 Interferon Sciences, manufactured by Purdue Frederick Co. Contains a mixture of natural alpha interferon with the brand Alferon, available from Norwalk, Conn.
    [53] The term “non-CIFN IFN-α” also includes derivatives of non-CIFNIFN-α induced to alter certain properties, such as serum half-life. As such, the term “non CIFNIFN-α” refers to glycosylated non-CIFNIFN-α; Non-CIFNIFN-α derived from polyethylene glycol ("pegylated IFN-α"); analogs thereof. PEGylated IFN-α and a method of preparing the same are described in U. S. Patent Nos. 5,382, 657; 5,981, 709; 5,824, 784; 5,985, 265; And 5,951, 974. PEGylated IFN-α is PEG (Roferon, Hoffman La-Roche, Nutley, NJ) conjugated to interferon alpha-2a, interferon alpha 2b (Intron, Schering-Plough, Madison, NJ), interferon alpha-2c (Berofor Conjugates of PEG, including the above-described IFN-α molecules, including, but not limited to, Alpha, Boehringer Ingelheim, Ingelheim, Germany).
    [54] The term "conservative IFN-α" (referred to as "CIFN" and "IFN-con") is described in US Pat. Nos. 4,897, 471 and CIFN as described in 4,695, 623 (ie, Examples 7,8 or 9) and specific products available from Amgen, Inc., (Infergen0, Amgen, Thous and Oaks, Calif.) do. The term is US Pat. Nos. Amino acid sequences designated as IFN-con l , IFN-con 2 , IFN-con 3 disclosed in 4,695, 623 and 4,897,471, including but not limited to. DNA sequences encoding IFN-con can be synthesized as described in the patents mentioned above or in other standard methods.
    [55] Additional remedies
    [56] CIFN treatment in accordance with the present invention may be performed in conjunction with the treatment of non-HCV diseases and disorders experienced by individuals with HCV. Such diseases include human immunodeficiency virus (HIV) hepatitis; Diseases include, but are not limited to, diseases associated with HIV hepatitis and include fungal hepatitis, respiratory hepatitis, eye hepatitis, Kaposi's sarcoma, and the like.
    [57] CIFN (in separate formulations; simultaneously in the same formulation, within approximately 48 hours, within approximately 36 hours, within approximately 24 hours, within approximately 16 hours, within approximately 12 hours, within approximately 8 hours, within approximately 4 hours, approximately 2 hours) Within hours, within about 1 hour, within about 30 minutes, or within about 15 minutes or less)) with one or more additional therapeutic agents. Therapeutic agents that may be administered as a combination therapy are anti-inflammatory, anti-viral, antifungal, anti-antibacterial, antibiotic, livemeva, saltricomono, analgesic, anti-tumor disease, antihypertensive, anti-microbial and / or Including but not limited to steroid reagents.
    [58] In some embodiments, the patient is treated with a combination of IFN-α and one or more of the following; Beta-lactam antibiotics, tetracycline, chloroamphenicol, neomycin, gramicidine, bacitracin, sulfonamide. Nitrofuranzone, nalidixic acid, cortisone, hydrocortisone, betamethasone, dexamethasone, fluorotolone, prednisolone, triamcinolone, indomethacin, sulindac, acyclic ratio, amantadine, rimantadine, recombinant water soluble CD4 (rsCD4), anti- Receptor antibodies (ie, rhinoviruses), nevirapine, Vistide ™ , trisodium phosphonoformate (Foscarnet ™ ), palmccloby, pencicloby, balaccloby, nucleic acid / proliferation inhibitors, zidobudine (AZT , Retrovir, didoxynosine (ddT, Videz), stavudine (d4T, Zenit), zalcitabine (didioxycytosine, ddC, Vivid), nevirapine (Viramune TM ), lamivudine (Epivir, 3TC), protease inhibitors , sakwi butterfly (InviraseTM, fortovase TM), ritonavir (Norvir), nelpi butterfly (Viracept TM), efavirenz (Sustiva), Ava carbidopa (Ziagen TM), M. frame bow (Agenerase TM) indinavir (Crixivan TM) in , Gansicloby, AzDU, Delavidin (Rescriptor), Kaletra, Trige Rain, rifampin, clatyromycin, erythropoietin, monarch stimulating factors (G-CSF and GM-CSF), non-nucleoside reverse transcriptase inhibitors, nucleoside inhibitors, adriamycin, fluorouracil, meto Tresate, asparaginase and combinations thereof.
    [59] Formulation and Input Routes
    [60] CIFN and ribavirin are generally administered to an individual in the form of a formulation (ie, in the same or separate formulation) together with a pharmaceutically acceptable additive. Various pharmaceutically acceptable additives are known in the art and need not be discussed in detail here. Pharmaceutically acceptable additives are described, for example, in A. Gennaro (2000) "Remington: The Science and Practice of Pharmacy", 20th edition, Lippincott, Williams, &Wilkins; Pharmaceutical Dosage forms and Drug Delivery Systems (1999) H. C. Ansel et al. , eds 7 ed., Lippincott, Williams, &Wilkins; and Handbook of Pharmaceutical Excipients (2000) A. H. Kibbe et al., eds., 3rd ed. Amer. It has been described in various publications, including Pharmaceutical Assoc.
    [61] As described herein, the therapeutic agents CIFN and ribavirin, as well as additional therapeutic agents, may be administered orally, subcutaneously, intramuscularly, parenterally for combination therapy. CIFN and ribavirin are administered by the same route of administration or by another route of administration. Therapeutics include oral, rectal, nasal, topical (including percutaneous, aerosol, buccal and sublingual), vaginal, parenteral (including subcutaneous, intramuscular, intravenous and intradermal), intravesicular or affected organs. It may be administered by appropriate means.
    [62] The therapeutic agent is administered in unit dosage form and prepared by methods known in the art. Such methods include combining a compound of the present invention with a pharmaceutically acceptable carrier or diluent which constitutes one or more accessory ingredients. Pharmaceutically acceptable carriers are selected based on the selected route of administration and the selected route of standard pharmaceutical practice. Each carrier must be "pharmaceutically acceptable" in the sense of being compatible with the other ingredients of the formulation and not damaging the test body. The carrier must be solid or liquid and the type is selected based on the dosage form used.
    [63] Examples of suitable solid carriers include lactose, sucrose, gelatin, agar and bulk powder. Examples of suitable liquid carriers include esters, emulsions, syrups or alchemy solutions, suspensions, solutions and / or suspensions, water including solutions and / or suspensions reconstituted from non-boiling particles and effervescent preparations reconstituted from boiling particles, Pharmaceutically acceptable fats and oils, alcohols or other organic solvents. Such liquid carriers are, for example, suitable solvents, preservatives, emulsifiers, suspending agents, diluents, sugar additives, thickeners, solubilizers. Preferred carriers include edible oils such as corn or canola oil. Polyethylene glycol, ie PEG, is a good carrier.
    [64] Drug delivery devices or systems that provide a dosing regimen of the invention can be used. Various drug delivery devices and systems are known to those skilled in the art.
    [65] Determine the effectiveness of treatment
    [66] Whether the dependent method is effective in treating HCV hepatitis can be determined by measuring parameters associated with HCV hepatitis, including viral load, or liver fibrosis.
    [67] Viral load can be measured by measuring viral titer or level in serum. Such methods include quantitative polymerase chain reaction (PCR) and branched DNA (bDNA) testing. Quantitative assays have been developed to measure the viral load (titer) of HCV RNA. Quantitative reverse transcription PCR (RT-PCR) (Amplicor HCV Monitor ™ , Roche Molecular Systems, New Jersey); Many such assays are commercially available, including and branched DNA (deoxyribonuvic acid) signal amplification assays (Quantiplex ™ HCV RNA Assay (bDNA), Chiron Corp., Emeryville, California). Gretch et al. (1995) Anfz. Intern. Med. 123: 321-329. Reference
    [68] Another method of determining viral load is to measure the level of serum antibodies against HCV. Methods for measuring serum antibodies against HCV are standard in the art and include enzyme immunoassays and recombinant immunoblot assays, both methods contacting serum samples with one or more HCV antigens and enzymatically labeled secondary antibodies ( That is, goat anti-human IgG) is used to detect antibodies that bind to HCV antigens. Weiss et al. (1995) Mayo Clin. Proc. 70: 296-297; and Gretch (1997) Hepatology 26: 43S-47S.
    [69] Virus titers are the most important indicator of the effectiveness of dosing regimens and other variables can also be measured as secondary indicators of efficiency. Secondary variables include a decrease in liver fibrosis and a decrease in serum levels of certain proteins as described below. Liver biopsy samples are analyzed to determine hepatic fibrosis reduction. Liver biopsy analysis involves the evaluation of two major components: the assessment of severeness and ongoing disease activity, assessed as "grade", affected by hyperinflammatory and fibrosis, and assessed as "stage" reflecting long-term disease progression. Histopathic or Remodeling. Brunt (2000) Hepatol. 31: 241-246; and METAVIR (1994) Hepatology 20: 15-20. Based on the analysis of the liver biopsy, a score is allocated. There are many standard scoring systems that provide a quantitative assessment of the degree and fidelity of fibrosis. This includes the METAVIR, Knodell, Scheuer, Ludwig and Ishak scoring systems.
    [70] Serum markers of hepatic fibrosis can also be assessed to indicate the effectiveness of the method of treatment of the subject. Serum markers of hepatic fibrosis include, but are not limited to, hyaluronic acid, N-terminal procollagen III peptide, 7S domain of type IV collagen, C-terminal procollagen I peptide, laminin.
    [71] Still other biochemical markers of hepatic fibrosis include a-2-macroglobulin, heptoglobulin, gamma globulin, apolipoprotein A, gamma glutamyl transpeptidase. Another secondary indicator of therapeutic curing efficiency is the serum level of serum alanine aminotransferase (ALT). Serum ALT levels are measured using standard assays. Generally, ALT levels of about 80 or less, about 60 or less, about 50 or less, or about 40 international units per liter of serum are considered normal. In some embodiments, the effective amount of IFNa comprises an ALT level of about 200 IU or less, about 150 IU or less, about 125 IU or less, about 100 IU or less, about 90 IU or less, about 80 IU or less, about 60 IU or less, or about 40 IU or less. It is an amount effective to reduce.
    [72] Test body suitable for treatment
    [73] Individuals diagnosed clinically, such as those infected with HCV, are suitable for treatment with the methods of the present invention. Individuals infected with HCV are identified as having HCV RNA in their blood and / or have anti-HCV antibodies in the serum. Such individuals include individuals who are anti-HCV eliza positive and those who have received a positive recombinant immune assay (RIBA). Such individuals have improved serum ALT levels.
    [74] Patients with particular benefit of the treatment of the present invention are patients who did not respond to previous HCV treatment (referred to as "non-responders") and patients who initially responded to previous treatment but did not maintain a treatment response (referred to as "relapsers" Patients with treatment failure). Previous treatment may generally include IFN-α monotherapy or IFN-α combination therapy, which may include administration of IFN-α and antiviral agents such as ribavirin. In a non-limiting embodiment, the individual has at least about 10 5 , at least about 5 × 10 5 , or at least about 10 6 , genomic copy of HCV titers per ml of serum.
    [75] Although the present invention has been described with reference to specific embodiments, it should be understood by those skilled in the art that various changes may be made and equivalents substituted without departing from the true spirit and scope of the invention. In addition, certain circumstances, materials, components of materials, processes, process steps or steps should be altered to suit the true spirit and scope of the invention. All such changes should fall within the scope of the claims appended hereto.
    权利要求:
    Claims (12)
    [1" claim-type="Currently amended] A method for treating a hepatitis C virus infection in an individual, comprising administering conservative interferon-α (CIFN) and ribavirin, wherein CIFN and ribavirin are administered in a therapeutic regimen effective to achieve a sustained viral response. The treated individual has failed the previous IFN-α based treatment but not CIFN treatment.
    [2" claim-type="Currently amended] The method of claim 1, wherein the individual has not responded to previous IFN-α-based treatment that is not CIFN treatment.
    [3" claim-type="Currently amended] The method of claim 1, wherein the treatment regimen comprises administration of 3 μg CIFN three times a week for 24 weeks, and 1000 to 1200 mg ribavirin per day during the treatment regimen.
    [4" claim-type="Currently amended] The method of claim 1, wherein the treatment regimen comprises administration of 9 μg CIFN three times a week for 24 weeks, and 1000 to 1200 mg ribavirin per day during the treatment regimen.
    [5" claim-type="Currently amended] The method of claim 1, wherein the treatment regimen comprises administering 15 μg CIFN three times a week for 24 weeks and between 1000 and 1200 mg ribavirin per day during the treatment regimen.
    [6" claim-type="Currently amended] The method of claim 1, wherein the treatment regimen comprises administering 9 μg CIFN per day for 24 weeks and from 1000 to 1200 mg ribavirin per day during the treatment regimen.
    [7" claim-type="Currently amended] The method of claim 1, wherein the treatment regimen comprises administration of 9 μg CIFN per day for 48 weeks and from 1000 to 1200 mg ribavirin per day during the treatment regimen.
    [8" claim-type="Currently amended] The method of claim 1, wherein the treatment regimen comprises administering 15 μg CIFN per day for 24 weeks, and 1000 to 1200 mg ribavirin per day during the treatment regimen.
    [9" claim-type="Currently amended] The method of claim 1, wherein the treatment regimen comprises administering 15 μg CIFN per day for 48 weeks and between 1000 and 1200 mg ribavirin per day during the treatment regimen.
    [10" claim-type="Currently amended] The method of claim 1, wherein the treatment regimen comprises administration of 9 μg CIFN three times weekly for 48 weeks, and 1000 to 1200 mg ribavirin per day during the treatment regimen.
    [11" claim-type="Currently amended] The method of claim 1, wherein the treatment regimen comprises administering 15 μg CIFN three times weekly for 48 weeks, and 1000 to 1200 mg ribavirin per day during the treatment regimen.
    [12" claim-type="Currently amended] The method of claim 1, wherein the treatment regimen comprises administering 18 μg CIFN three times weekly for 48 weeks, and 1000 to 1200 mg ribavirin per day during the treatment regimen.
    类似技术:
    公开号 | 公开日 | 专利标题
    Herrmann et al.2003|Effect of ribavirin on hepatitis C viral kinetics in patients treated with pegylated interferon
    Santantonio et al.2005|Efficacy of a 24-week course of PEG-interferon α-2b monotherapy in patients with acute hepatitis C after failure of spontaneous clearance
    JP2015098501A|2015-05-28|Combination of nucleoside polymerase inhibitor with macrocyclic protease inhibitor and use thereof in treatment of hepatitis c, liver fibrosis and impaired liver function
    Di Bisceglie et al.2002|Optimal therapy of hepatitis C
    Keating et al.2014|Sofosbuvir: first global approval
    Moreno et al.2004|Short Communication High rate of didanosinerelated mitochondrial toxicity in HIV/HCV-coinfected patients receiving ribavirin
    Gentile et al.2014|Dasabuvir: a non-nucleoside inhibitor of NS5B for the treatment of hepatitis C virus infection
    RU2145235C1|2000-02-10|Human interferon-containing therapeutic composition, interferon-base pharmaceutical preparation |
    TWI241913B|2005-10-21|Use of PEG-IFN-alpha and ribavirin for the treatment of chronic hepatitis C
    Buti et al.2002|Viral kinetics in genotype 1 chronic hepatitis C patients during therapy with 2 different doses of peginterferon alfa-2b plus ribavirin
    TWI454263B|2014-10-01|Combination therapy for treating hcv infection
    JP3228512B2|2001-11-12|Compositions and methods for treating hepatitis C
    Asselah et al.2011|New direct‐acting antivirals' combination for the treatment of chronic hepatitis C
    Hayashi et al.2006|Antiviral therapy for chronic hepatitis C: past, present, and future
    US6007805A|1999-12-28|Use of interferon subtype alpha-8 | to treat viral infections of the liver
    US6299872B1|2001-10-09|Combination therapy for chronic hepatitis c infection
    AU2005220271B2|2005-11-03|Combination therapy comprising ribavirin and interferon alpha in antiviral treatment naive patients having g chronic hepatitis C infection
    Pawlotsky et al.2004|Antiviral action of ribavirin in chronic hepatitis C
    Hassanein et al.2004|The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C
    JP2005508943A|2005-04-07|Treatment of hepatitis virus infection with multiphase interferon delivery profile
    Sulkowski2003|Anemia in the treatment of hepatitis C virus infection
    Scott et al.2002|Interferon-α-2b Plus Ribavirin
    AU749924B2|2002-07-04|Combination therapy for eradicating detectable HCV-RNA in patients having chronic hepatitis C infection
    Bräu2003|Update on chronic hepatitis C in HIV/HCV-coinfected patients: viral interactions and therapy
    Foster2004|Past, present, and future hepatitis C treatments
    同族专利:
    公开号 | 公开日
    AR036697A1|2004-09-29|
    HU0401657A2|2004-11-29|
    JP2005508342A|2005-03-31|
    PL369129A1|2005-04-18|
    BR0212917A|2004-12-21|
    WO2003028755A1|2003-04-10|
    ZA200402232B|2005-03-22|
    CA2460589A1|2003-04-10|
    US20050031586A1|2005-02-10|
    MXPA04002724A|2004-07-05|
    NO20041855L|2004-04-27|
    EP1435998A4|2005-03-02|
    IL160881D0|2004-08-31|
    EP1435998A1|2004-07-14|
    PL368718A1|2005-04-04|
    CN1558771A|2004-12-29|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2001-09-28|Priority to US32608801P
    2001-09-28|Priority to US60/326,088
    2002-09-24|Application filed by 인터뮨, 인크.
    2002-09-24|Priority to PCT/US2002/030445
    2004-05-31|Publication of KR20040045022A
    优先权:
    申请号 | 申请日 | 专利标题
    US32608801P| true| 2001-09-28|2001-09-28|
    US60/326,088|2001-09-28|
    PCT/US2002/030445|WO2003028755A1|2001-09-28|2002-09-24|Method for treating hepatitis c virus infection in treatment failure patients|
    [返回顶部]